1050500-29-2

1050500-29-2 structure

Name: AST-1306 (TsOH)
Chemical Name: N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]prop-2-enamide,4-methylbenzenesulfonic acid
CAS Number: 1050500-29-2
Molecular Formula: C₃₁H₂₆ClFN₄O₅S
Molecular Weight: 621.078
Catalog: Biochemical Inhibitor Protein tyrosine kinase
Create Date: 2018-04-25 08:00:00
Modify Date: 2025-08-20 16:39:51
Allitinib tosylate (AST-1306 TsOH) is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases.IC50 value: 0.5/3 nM (EGFR/Erb2)[1]Target: EGFR/Erb2;Mutant EGFR T790M/L858RAllitinib functions as an irreversible inhibitor, most likely through covalent interaction with Cys797 and Cys805 in the catalytic domains of EGFR and ErbB2, respectively. Further studies showed that Allitinib inactivated pathways downstream of these receptors and thereby inhibited the proliferation of a panel of cancer cell lines. Allitinib is a potent(pM) and selective inhibitor of EGFR and ErbB4 (IC50 = 500pM and 800 pM, respectively). AST-1306 blocks phosphorylation of EGFR and also prevents downstream pathways. Allitinib also dose-dependently inhibits EGF-induced EGFR phosphorylation in the A549 cancer cell line.

Name	N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]prop-2-enamide,4-methylbenzenesulfonic acid
Synonyms	AST-6 CS-1209 AST-1306 TsOH 2-Propenamide, N-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-, 4-methylbenzenesulfonate (1:1) cc-284 N-[4-({3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)-6-quinazolinyl]acrylamide 4-methylbenzenesulfonate (1:1) S1471_Selleck AST-1306 (TsOH)

Description	Allitinib tosylate (AST-1306 TsOH) is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases.IC50 value: 0.5/3 nM (EGFR/Erb2)[1]Target: EGFR/Erb2;Mutant EGFR T790M/L858RAllitinib functions as an irreversible inhibitor, most likely through covalent interaction with Cys797 and Cys805 in the catalytic domains of EGFR and ErbB2, respectively. Further studies showed that Allitinib inactivated pathways downstream of these receptors and thereby inhibited the proliferation of a panel of cancer cell lines. Allitinib is a potent(pM) and selective inhibitor of EGFR and ErbB4 (IC50 = 500pM and 800 pM, respectively). AST-1306 blocks phosphorylation of EGFR and also prevents downstream pathways. Allitinib also dose-dependently inhibits EGF-induced EGFR phosphorylation in the A549 cancer cell line.
Related Catalog	Research Areas >> Cancer
Target	EGFR:0.5 nM (IC50) ErbB2:3 nM (IC50) ErbB1
References	[1]. Xie H, Lin L, Tong L et al. AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One. 2011;6(7):e21487.

Hazard Codes	Xi

897383-62-9

104-15-4

~97%

1050500-29-2

Literature: Guo, Jianhui; Jiang, Yong Patent: US2012/4249 A1, 2012 ; Location in patent: Page/Page column 8 ;

19815-16-8

1050500-29-2

Literature: US2012/4249 A1, ;

202197-26-0

1050500-29-2

Literature: US2012/4249 A1, ;

851653-35-5

1050500-29-2

Literature: US2012/4249 A1, ;